TROV - .80 Pre-market now at .84/.90 Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy http://stockcharts.com/c-sc/sc?s=TROV&p=D&b=5&g=0&i=t62062666858&r=1502886112910 http://stockcharts.com/c-sc/sc?s=TROV&p=W&b=5&g=0&i=t26335904843&r=1502886133819